<DOC>
	<DOCNO>NCT00160251</DOCNO>
	<brief_summary>The primary objective study determine safe effective dose range boceprevir ( SCH 503034 ) combination PEG-Intron adult subject chronic hepatitis C without cirrhosis , fail adequate course combination therapy peginterferon-alfa plus ribavirin . A secondary objective explore whether ribavirin provide additional benefit combine PEG-Intron plus boceprevir .</brief_summary>
	<brief_title>Boceprevir ( SCH 503034 ) Plus Peg-Intron , With Without Added Ribavirin , Patients With Chronic Hepatitis C , Genotype 1 , Who Did Not Respond Previous Treatment With Peginterferon Alfa Plus Ribavirin ( Study P03659AM2 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Key inclusion criterion : Documented infection chronic hepatitis C ( CHC ) , genotype 1 . Documented failure respond adequate course treatment ( minimum 12 week ) peginterferonalfa plus ribavirin ( failure define &lt; 2 log drop HCVRNA 12 week therapy never become Hepatitis C Virus Ribonucleic Acid ( HCV ) RNA negative ) No evidence cirrhosis liver biopsy . Results physical examination laboratory test within specify range . Abstinence use abuse substance . Key exclusion criterion : Women pregnant nursing child . Patients cirrhosis , coinfection Hepatitis B human immunodeficiency virus ( HIV ) , AfricanAmerican patient ( protocol amendment 2 , AfricanAmerican patient enroll ) . Previous treatment Hepatitis C Virus ( HCV ) polymerase protease inhibitor . Patients relapse follow response previous treatment . Evidence advance liver disease , liver disease cause CHC . Preexisting psychiatric condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>PEG-Intron</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Protease Inhibitor</keyword>
</DOC>